的 探究不同血液灌流(hemoperfusion,HP)频率对维持性血液透析(maintenance hemodialysis,MHD)患者蛋白质能量消耗(protein-energy wasting,PEW)的影响。 方法 共纳入80例患者，根据HP治疗频率分为无HP(A)组、每月1次HP组(B)组、每半月1次HP(C)组、每周1次HP(D)组，每组20例患者，随访半年。比较4组患者治疗前后PEW患病率、营养不良炎症评分(malnutrition-inflammation score,MIS)及相关生化指标。 结果 治疗前，4组患者MIS评分(F=2.194，P=0.096)、PEW患病率(χ2=0.579，P=0.901)、前白蛋白(PA)(F=0.258，P=0.855)、白蛋白(Alb)(F=0.187，P=0.905)、甲状旁腺激素(PTH)(F=0.780，P=0.509)、血红蛋白(Hb)(F=1.823，P=0.150)、β2-微球蛋白(β2-MG)(F=1.833， P=0.148)、C反应蛋白(CRP)(F=0.432，P=0.731)水平比较均无统计学差异；治疗后，D组有15例患者退出试验，C组MIS评分(C-A：t=4.391,P≤0.001；C-B：t=-2.871,P=0.006)、PTH(C-A：t=4.098,P=0.001；C-B： t=-2.551,P=0.047)、β2-MG(C-A：t=5.688,P＜0.001；C-B：t=-3.207,P=0.002)、CRP(C-A：t=4.293, P＜0.001；C-B：t=-2.843,P=0.006)水平低于A、B组；C组PA(C-A：t=-3.177,P=0.002；C-B：t=2.196, P=0.032)、Alb(C-A：t=-5.540,P＜0.001；C-B：t=2.196,P=0.010)水平高于A、B组；C组Hb(t=-3.733,P＜0.001)水平高于A组，与B组比较无统计学差异(t=1.451,P=0.152)；C组PEW患病率(χ2=6.465,P=0.011)低于A组，A、B 2组间PEW患病率无统计学差异(χ2=2.506，P=0.113)。 结论 半月1次的HP治疗可以明显改善MHD患者的营养状况，降低PEW的患病率。
【关键词】维持性血液透析；蛋白质能量消耗；血液灌流；尿毒症毒素
The Influence of Different Frequency of Hemoperfusion on Protein-energy Wasting of Maintenance Hemodialysis Patients YIN Yi-fang1,MOU Jiao1,YANG Ying1,TANG Jian-ying1 1Department of Nephrology and Urology Center,University Town Hospital Affiliated to Chongqing Medical University, Chongqing 400715,China
Corresponding author: TANG Jian-ying, Email:800273@hospital.cqmu.edu.cn
【Abstract】Objective To investigate the impact of different hemoperfusion (HP) frequencies on protein-energy wasting (PEW) in patients undergoing maintenance hemodialysis (MHD). Methods Eighty patients were included and divided based on HP treatment frequency into four groups: no HP (group A), monthly HP (group B), bi-monthly HP (group C) and weekly HP (group D) , with 20 patients in each group. All patients were followed up for six months, then the prevalence of PEW, malnutrition-inflammation score (MIS), and related serum biochemical indicators were analyzed before and after treatment. Results Before treatment, there were no significant differences (P＞0.05) in MIS scores (F=2.194, P=0.096), the prevalence of PEW (χ2=0.579, P=0.901), level of pre-albumin (PA) (F=0.258, P=0.855), albumin (Alb) (F=0.187, P=0.905), parathyroid hormone (PTH) (F=0.780, P=0.509), hemoglobin(Hb)(F=1.823，P=0.150), β2-microglobulin (β2-MG) (F=1.833, P=0.148), and C-Reactive protein (CRP) (F=0.432, P=0.731) among the four groups. After treatment, there were 15 patients who withdrew from the trial in Group D. The group C had lower levels of MIS score (C-A: t=4.391, P＜0.001; C-B: t=-2.871, P=0.006), PTH (C-A: t=4.098, P=0.001; C-B: t=-2.551, P=0.047),β2-MG (C-A: t=5.688, P＜0.001; C-B: t=-3.207, P=0.002), CRP (C-A:t=4.293, P＜0.001; C-B: t=-2.843, P=0.006) compared with group A and B); and higher level of PA(C-A: t=-3.177, P=0.002; C-B: t=2.196, P=0.032). Alb (C-A: t=-5.540, P＜0.001; C-B: t=2.196, P=0.010) than Groups A and B. Group C had higher level of Hb (t=-3.733, P＜0.001) than group A, and no significant difference with group B (t=1.451, P=0.152). The prevalence of PEW in group C (χ2=6.465, P=0.011) was significantly lower than group A, but there was no significant difference between group A and group B (χ2=2.506, P=0.113). Conclusion Bimonthly HP treatment can obviously improve the nutritional status of patients with MHD and reduce the prevalence of PEW.
[1]Carrero JJ, Thomas f, Nagy K, et? al. Global prevalence of protein-energy wasting in kidney disease: a meta-analysis of contemporary observational studies from the international society of renal nutrition and metabolism. J Ren Nutr. 2018;28(6):380–392.
[2]Cao M, Zheng S, Zhang W, et al. Progress in the study of nutritional status and selenium in dialysis patients[J]. Annals of Medicine, 2023, 55(1): 2197296.
[3]He Y, Liu R, Zhu M, et al. The browning of white adipose tissue and body weight loss in primary hyperparathyroidism[J]. EBioMedicine, 2019, 40: 56-66.
[4]Pivari F, Mingione A, Piazzini G, et al. Curcumin supplementation (Meriva?) modulates inflammation, lipid peroxidation and gut microbiota composition in chronic kidney disease[J]. Nutrients, 2022, 14(1): 231.
[5]Van Duong T, Wu P Y, Wong T C, et al. Mid-arm circumference, body fat, nutritional and inflammatory biomarkers, blood glucose, dialysis adequacy influence all-cause mortality in hemodialysis patients: A prospective cohort study[J]. Medicine, 2019, 98(12).
[6]Hendriks fK, Smeets JSJ, Broers NJH, et? al. End-stage renal disease patients lose a substantial amount of amino acids during hemodialysis. J Nutr. 2020;150(5):1160–1166.
[7]Fouque, D., Kalantar-Zadeh, K., Kopple, J.,et al.A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney international, 2007, 73(4):391-8.
[8]Kir S, Komaba H, Garcia A P, et al. PTH/PTHrP receptor mediates cachexia in models of kidney failure and cancer[J]. Cell metabolism, 2016, 23(2): 315-323.
[9]Sharma B, Dabur R. Role of pro-inflammatory cytokines in regulation of skeletal muscle metabolism: a systematic review[J]. Current medicinal chemistry, 2020, 27(13): 2161-2188.
[10]王萌,蒋红利,何荃等.血液透析联合血液灌流治疗对慢性肾衰竭患者肾功能、微炎症状态和血液净化效果的影响[J].现代生物医学进展,2018,18(08):1511-1514+1413.DOI:10.13241/j.cnki.pmb.2018.08.022.
[11]Snauwaert E, Van Biesen W, Raes A, et al. Haemodiafiltration does not lower protein-bound uraemic toxin levels compared with haemodialysis in a paediatric population[J]. Nephrology Dialysis Transplantation, 2020, 35(4): 648-656.
[12]何琦,梁凌,蒋金玉.血液透析联合血液灌流对尿毒症继发甲状旁腺功能亢进的疗效[J].中国临床研究,2018,31(02):189-192.
[13]Nguyen Huu D, Dao Bui Quy Q, Nguyen Thi Thu H, et al. A Combination of Hemodialysis with Hemoperfusion Helped to Reduce the Cardiovascular-Related Mortality Rate after a 3-Year Follow-Up: A Pilot Study in Vietnam[J]. Blood Purification, 2021, 50(1): 65-72.
[14]Soppert J, Lehrke M, Marx N, et al. Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting[J]. Advanced Drug Delivery Reviews, 2020, 159: 4-33.
[15]Li J, Li H, Deng W, et al. The Effect of Combination Use of Hemodialysis and Hemoperfusion on Microinflammation in Elderly Patients with Maintenance Hemodialysis[J]. Blood Purification, 2022, 51(9): 739-746.
[16]Mollahosseini A, Abdelrasoul A, Shoker A. A critical review of recent advances in hemodialysis membranes hemocompatibility and guidelines for future development[J]. Materials Chemistry and Physics, 2020, 248: 122911.
[17]陈舜杰,叶朝阳,陈静等. 血浆置换、血液灌流在人工肝支持治疗中的比较 [J]. 实用诊断与治疗杂志, 2006, (10): 725-727.
[18]陶怡婷.血液净化技术在危重患者治疗中的应用进展[J].中国现代医生,2020,58(19):188-192.
[19]Nishikawa H, Enomoto H, Nishiguchi S, et al. Liver cirrhosis and sarcopenia from the viewpoint of dysbiosis[J]. International Journal of Molecular Sciences, 2020, 21(15): 5254.
[20]Zhang Z Y, Li M X, Yu H, et al. Combination of multiple hemodialysis Modes: Better treatment Options for patients under maintenance hemodialysis[J]. Therapeutics and clinical risk management, 2021: 127-133.
[21]周俊,杨文君,刘芳.血液灌流联合血液透析对毒素清除及患者营养状态的影响[J].中国卫生检验杂志,2017,27(16):2356-2358+2361.
[22]Lu W, Jiang G, Shanghai HP-HD Consensus Group. Hemoperfusion in Maintenance Hemodialysis Patients[J]. Blood Purification, 2022, 51(10): 803-811.
